As reported on Medscape, global phase 3 clinical trial suggests that veligrotug, an investigational monoclonal antibody targeting the insulin-like growth factor‑1 receptor (IGF‑1R), may offer
As reported on Becker’s Hospital Review, the U.S. Food and Drug Administration (FDA) has issued updated guidance targeting how telehealth companies promote compounded medications, particularly
As reported on CNET, parents and caregivers now have a new option to help monitor children’s blood sugar levels at home. The US Food and
As reported on Pharmaceutical Technology, the US Food and Drug Administration (FDA) has approved a new adjuvant treatment option for adults with clear cell renal
As reported on MedCity News, the U.S. Food and Drug Administration (FDA) has introduced a new regulatory pathway that could reshape how treatments are developed
As reported on Business Wire, Gilead Sciences has announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application for
I grew up believing health was something you could control if you were disciplined enough. In my Chinese immigrant family, my father talked constantly about
As shared in a recent press release, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to teplizumab (Tzield) for a new pediatric
As reported by Pharmaceutical Technology, Alkermes has announced that its investigational therapy alixorexton has received orphan drug designation from both US and European regulators, marking
As reported on PharmaBiz, AstraZeneca has announced that the US Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA)
As reported on MedCity News, the U.S. Food and Drug Administration (FDA) has issued draft guidance encouraging the thoughtful use of Bayesian statistical approaches in
Emerging evidence, as reported by the American Academy of Ophthalmology, suggests that glycemic surveillance should be considered for all patients undergoing teprotumumab therapy for thyroid
When Seth Wharton was only one month old, doctors repaired his narrow heart valve. Then, five years later, he was referred to UAB Cardiovascular Institute
Madrid, June 5th, 2026 The Dravet Syndrome Foundation received the Merck Innovation Talent Award for a scientific publication regarding a tool that assesses neuropsychiatric issues
As reported on Business Wire, TearSolutions, a clinical-stage biotechnology company focused on ophthalmic therapies, has announced key regulatory and clinical progress for its investigational drug
Website: https://fabrynetwork.org/youngadults Instagram Young Adults: @fabryyoungadults Instagram FIN: @fabryintnetwork 11 June 2026 – FIN launches international Young Adults Guidebook created by and for young adults
When David Williams noticed a slight tremor in his right hand, he convinced himself it was something manageable, perhaps a compressed nerve that would eventually
In a notable update for dermatologic and consumer health, the U.S. Food and Drug Administration (FDA) released a press statement disclosing their authorization of the
Hidradenitis suppurativa (HS) is more than just a skin condition. It is a chronic inflammatory disease that can cause painful lumps, abscesses, and scarring, most often in areas where skin rubs together, such as the underarms, groin, buttocks, and under the breasts.
HS can affect people of all backgrounds, but it most commonly develops after puberty and is more frequently diagnosed in women. Because symptoms are often misunderstood or dismissed, many people face delays in getting the care and support they need.
Every HS journey is different, and every story matters.
If you're living with HS, we'd love to hear from you. Click here: ow.ly/qWWU50ZkK9E or the link in our bio to get involved!
#HidradenitisSuppurativa #HSAWARENESS #chronicillness #patientadvocacy #PatientWorthy #invisibleillness #RareDiseaseCommunity #shareyourstory #PatientWorthy
From Jack and our friends Visual Snow InitiativeHi,I’m Jack, a 36-year-old living in the United Kingdom.
I have never been one for opening up. I am quite a private person, and putting myself out there is difficult for me. I have been inspired to do so by all the stories I have read through Warrior of the Week.
I was born with Axenfeld-Rieger Syndrome, a genetic condition I inherited from my father. I was born with malformed eye structures, including uniquely shaped pupils and irregular drainage systems. One symptom of ARS is congenital glaucoma. Glaucoma is a condition that affects the drainage of fluid from the eyes. When I was 19, the pressure in my right eye became uncontrollably high, despite being on the full range of medications. This is when I had my first glaucoma surgery, with a tube inserted into the eye to assist with the drainage of fluid. But when I awoke from this surgery, something wasn’t right. The tube had “worked too well.” The sudden and rapid reduction in fluid caused the eye to hemorrhage and the retina to detach fully. I have had no vision in my right eye since. I have since had two tubes fitted in my left eye without issues.
I was diagnosed with VSS in about 2020. I had always associated anything visual with ARS, glaucoma, and the trauma to my eyes. Thinking back on it, I may have been experiencing symptoms of VSS from quite a young age. I don’t remember ever seeing pitch black when I closed my eyes. It would always be a nebula of swirling colours. I have also had excessive floaters, ghosting, and starbursts for a long time.
I have always tried to have a “roll with the punches, get up and keep going” attitude when it comes to my visual health issues. But with VSS, it has been really tough to keep that mindset. It is always there, shimmering away. At home, at work, on days out with my daughter, and while playing football with the guys. It is relentless.
I have been aware of VSI for a few years now. They have done so much for the recognition and diagnosis of VSS. Their advocacy and continued research are great to see and give a lot of hope for the future of VSS treatment.
Our stories may be different, but we can be together in the experiences we share.
You are not alone.
New reports suggest that Attruby, a treatment for ATTR-CM, may also help preserve the kidney function of patients living with the condition. Read more here:
ow.ly/zRHG50ZlevF
#PatientWorthy #shareyourstory #ATTRCM #Attr #amyloidosis #attruby
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
